Simple Summary
Fibroblast Growth Factor Receptor-1 (FGFR1), a major receptor tyrosine kinase (RTK), regulates early embryonic development and organogenesis. However, overexpression of FGFR1 is seen in many human solid tumors and is associated with poor prognosis, resistance to multiple therapies and aggressive metastatic spread. Our aim was to study the mechanisms controlling FGFR1 activity, with an ultimate goal of identifying key therapeutic targets for solid tumors. We unexpectedly found that a major splice variant, FGFR1 IIIc, was sequestered in intracellular vesicles under normal conditions. We investigated this phenomenon in detail to identify the sequestration mechanism and further elucidated how the sequestration was released to permit receptor translocation to the plasma membrane (PM) in response to microenvironmental cues. The novel pathway, a first such mechanism identified for RTK, regulates PM localization of FGFR1 IIIc, thereby determining its signal output. This knowledge will aid in the development of next-generation strategies to silence FGFR1 in solid tumors.
Abstract
How human FGFR1 localizes to the PM is unknown. Currently, it is assumed that newly synthesized FGFR1 is continuously delivered to the PM. However, evidence indicates that FGFR1 is mostly sequestered in intracellular post-Golgi vesicles (PGVs) under normal conditions. In this report, live-cell imaging and total internal reflection fluorescence microscopy (TIRFM) were employed to study the dynamics of these FGFR1-positive vesicles. We designed recombinant proteins to target different transport components to and from the FGFR1 vesicles. Mouse embryoid bodies (mEBs) were used as a 3D model system to confirm major findings. Briefly, we found that Rab2a, Rab6a, Rab8a, RalA and caveolins are integral components of FGFR1-positive vesicles, representing a novel compartment. While intracellular sequestration prevented FGFR1 activation, serum starvation and hypoxia stimulated PM localization of FGFR1. Under these conditions, FGFR1 C-terminus acts as a scaffold to assemble proteins to (i) inactivate Rab2a and release sequestration, and (ii) assemble Rab6a for localized activation of Rab8a and RalA-exocyst to deliver the receptor to the PM. This novel pathway is named Regulated Anterograde RTK Transport (RART). This is the first instance of RTK regulated through control of PM delivery.